title: A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
authors.affiliation: Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
authors.forename: Anne Lynn S
authors.initials: AL
authors.lastname: Chang
authors.affiliation: Department of Dermatology, Stanford University School of Medicine, Redwood City, California2Department of Pathology, Stanford University School of Medicine, Palo Alto, California.
authors.forename: Jinah
authors.initials: J
authors.lastname: Kim
authors.affiliation: Department of Medicine-Head and Neck Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Richard
authors.initials: R
authors.lastname: Luciano
authors.affiliation: Department of Medicine-Head and Neck Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Loretta
authors.initials: L
authors.lastname: Sullivan-Chang
authors.affiliation: Department of Medicine-Head and Neck Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Alexander D
authors.initials: AD
authors.lastname: Colevas
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab